MedTrace Logo

Comparison of Remdesivir Versus Lopinavir/ Ritonavir and Remdesivir Combination in COVID-19 Patients

NCT04738045 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-03-17

No results posted yet for this study

Summary

Comparison outcomes of a large cohort of moderate and severe COVID-19 patients received remdesivir alone with patients who received remdesivir in combination with lopinavir/ ritonavir in addition to standard management.

Conditions

  • Covid19

Interventions

DRUG

Remdesivir

Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily.

DRUG

Lopinavir/ Ritonavir and Remdesivir combination

Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days

Sponsors & Collaborators

  • Beni-Suef University

    collaborator OTHER

  • Ahmed Essam

    lead OTHER

Principal Investigators

  • Rania M Sarhan, PhD · Beni-Suef University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2021-03-28
Completion
2021-04-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04738045 on ClinicalTrials.gov